RC, Frank MJ (2006). Making working memory work: a computational model of learning in the prefrontal cortex and basal ganglia. Neural Comput 18(2): 283–328.
Oades RD (2002). Dopamine may be ›hyper‹ with respect to noradrenaline metabolism, but ›hypo‹ with respect to serotonin metabolism in children with attention-deficit hyperactivity disorder. Behav Brain Res 130(1–2): 97–102.
Oades RD (2005). The Roles of Norepinephrine and Serotonin in Attenion Deficit Hyperactivity Disorder. In: Gozal D, Molfese DL (Eds.). Attention Deficit Hyperactivity Disorder: From Genes to Patients. Totowa, NJ: Humana Press. S. 97–130.
Oades RD (2006). Function and dysfunction of monamine interactions in children and adolescents with AD/HD. In: Levin ED (Ed.). Neurotransmitter Interactions and Cognitive Function. Basel: Birkhäuser. S. 207–244.
Oades RD (2007). Role of the serotonin system in ADHD: treatment implications. Expert Rev Neurother 7(10): 1357–74.
Oades RD, Muller B (1997). The development of conditioned blocking and monoamine metabolism in children with attention-deficit-hyperactivity disorder or complex tics and healthy controls: an exploratory analysis. Behav Brain Res 88(1): 95–102.
Oades RD, Daniels R et al. (1998). Plasma neuropeptide-Y levels, monoamine metabolism, electrolyte excretion and drinking behavior in children with attention-deficit hyperactivity disorder. Psychiatry Res 80(2): 177–86.
Ogdie MN, Bakker SC et al. (2006). Pooled genome-wide linkage data on 424 ADHD ASPs suggests genetic heterogeneity and a common risk locus at 5p13. Mol Psychiatry 11(1): 5–8.
Palsson E, Sellgren C, Rydén E, Kizza R, Pelanis A, Zetterberg H, Blennow K, Landén Mikael (2017). Cerebrospinal fluid monoamine metabolite profiles in bipolar disorder, ADHD and controls. J Neural Transm 124: 1135–1143.
Pliszka SR (2005). The neuropsychopharmacology of attention-deficit/hyperactivity disorder. Biol Psychiatry 57(11): 1385–90.
Prince J (2008). Catecholamine Dysfunction in Attention-Deficit/Hyperactivity Disorder. J Clin Psychopharmacol 28 (Suppl. 2): 39–45.
Rajkowski J, Majczynski H, Clayton E, Aston-Jones GS (2004). Activation of monkey locus coeruleus neurons varies with difficulty and performance in a target detection task. J Neurophysiol 92: 361–371.
Rapoport J, Quinn P et al. (1974). Platelet serotonin of hyperactive school age boys. Br J Psychiatry 125(2): 138–40.
Reimherr FW, Wender PH et al. (1984). Cerebrospinal fluid homovanillic acid and 5-hydroxy-indoleacetic acid in adults with attention deficit disorder, residual type. Psychiatry Res 11(1): 71–8.
Retz W, Freitag CM et al. (2008). A functional serotonin transporter promoter gene polymorphism increases ADHD symptoms in delinquents: interaction with adverse childhood environment. Psychiatry Res 158(2): 123–31.
Riikonen RS, Nokelainen P et al. (2005). Deep serotonergic and dopaminergic structures in fetal alcoholic syndrome: a study with nor-beta-CIT-single-photon emission computed tomography and magnetic resonance imaging volumetry. Biol Psychiatry 57(12): 1565–72.
Roessner V, Walitza S et al. (2007). Tetrahydroisoquinoline derivatives: a new perspective on monoaminergic dysfunction in children with ADHD? Behav Brain Funct 3(1): 64.
Roessner V, Manzke T et al. (2009a). Development of 5-HT transporter density and long-term effects of methylphenidate in an animal model of ADHD. World J Biol Psychiatry 26(1):1–5.
Roessner V, Sagvolden T et al. (2009a). MPH treatment normalizes elevated dopamine transporter density in an animal model of ADHD (submitted).
Ruskin DN, Bergstrom DA et al. (2001). Drugs used in the treatment of attention-deficit/hyperactivity disorder affect postsynaptic firing rate and oscillation without preferential dopamine autoreceptor action. Biol Psychiatry 49(4): 340–50.
Russell VA (2002). Hypodopaminergic and hypernoradrenergic activity in prefrontal cortex slices of an animal model for attention-deficit hyperactivity disorder– the spontaneously hypertensive rat. Behav Brain Res 130(1–2): 191–6.
Russell VA, Sagvolden T et al. (2005). Animal models of attention-deficit hyperactivity disorder. Behav Brain Funct 1: 9.
Sagvolden T, Johansen EB et al. (2005). A dynamic developmental theory of attention-deficit/hyperactivity disorder (ADHD) predominantly hyperactive/impulsive and combined subtypes. Behav Brain Sci 28(3): 397–419; discussion 419–68.
Schiffer WK, Volkow ND et al. (2006). Therapeutic doses of amphetamine or methylphenidate differentially increase synaptic and extracellular dopamine. Synapse 59(4): 243–51.
Shaw P, Sharp WS, Morrison M, Eckstrand K, Greenstein DK, Clasen LS, Evans AL, Rapoport JL (2009). Psychostimulant Treatment and the developing cortex in attention deficit hyperactivity. Am J Psychiatry 166(1): 58–63.
Shaywitz BA, Cohen DJ et al. (1977). CSF monoamine metabolites in children with minimal brain dysfunction: evidence for alteration of brain dopamine. A preliminary report. J Pediatr 90(1): 67–71.
Sheehan K, Lowe N et al. (2005). Tryptophan hydroxylase 2 (TPH2) gene variants associated with ADHD. Mol Psychiatry 10(10): 944–9.
Sheehan K, Hawi Z et al. (2007). No association between TPH2 gene polymorphisms and ADHD in a UK sample. Neurosci Lett 412(2): 105–7.
Shekim WO, Bylund DB et al. (1986). Platelet MAO and measures of attention and impulsivity in boys with attention deficit disorder and hyperactivity. Psychiatry Res 18(2): 179–88.
Shetty T, Chase TN (1976). Central monoamines and hyperkinase of childhood. Neurology 26(10): 1000–2.
Sikstrom S, Soderlund G (2007). Stimulus-dependent dopamine release in attention-deficit/hyperactivity disorder. Psychol Rev 114(4): 1047–75.
Solanto MV (2002). Dopamine dysfunction in AD/HD: integrating clinical and basic neuroscience research. Behav Brain Res 130(1–2): 65–71.
Spivak B, Vered Y et al. (1999). Circulatory levels of catecholamines, serotonin and lipids in attention deficit hyperactivity disorder. Acta Psychiatr Scand 99(4): 300–4.
Tripp G, Wickens JR (2008). Research review: dopamine transfer deficit: a neurobiological theory of altered reinforcement mechanisms in ADHD. J Child Psychol Psychiatry 49(7): 691–704.
Volkow ND, Ding YS et al. (1995). Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch Gen Psychiatry 52(6): 456–63.
Volkow ND, Wang G et al. (2001). Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci 21(2): RC121.
Walitza S, Renner TJ et al. (2005). Transmission disequilibrium of polymorphic variants in the tryptophan hydroxylase-2 gene in attention-deficit/hyperactivity disorder. Mol Psychiatry 10(12): 1126–32.
Watanabe Y, Fujita M et al. (1997). Brain dopamine transporter in spontaneously hypertensive rats. J Nucl Med 38(3): 470–4.
Wilens TE (2008). Effects of Methylphenidate on the Catecholaminergic Sytstem in Attention-Deficit/Hyperactivity Disorder. J Clin Psychopharmcaol 28 (Suppl. 2): S46–S53.
Williams
